Last reviewed · How we verify
NCT05504330
Cognitive Decline and Underlying Mechanisms in Asymptomatic Intracranial Artery Stenosis Patients
trial testing Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin in Asymptomatic Intracranial Stenosis in 100 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Anhui Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 August 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin — full drug profile →
Conditions studied
- Asymptomatic Intracranial Stenosis — all drugs for Asymptomatic Intracranial Stenosis →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Cerebrovascular Event — all drugs for Cerebrovascular Event →
Sponsor
Anhui Medical University
Who can join
Adults 18 to 80, any sex, with Asymptomatic Intracranial Stenosis or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to explore the mechanism of cognitive impairment in patients with asymptomatic intracranial atherosclerotic stenosis(ICAS),and to examine the natural history and the pathogenesis of asymptomatic ICAS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05504330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Aspirin Tablet, Clopidogrel Bisulfate Tablets and Atorvastatin
Trials testing the same drug.
- NCT06336174 — Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study · recruiting
- NCT04850001 — Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study · unknown
Other Anhui Medical University trials
Trials by the same sponsor.
- NCT07403591 — Mapsd Dual-target cTBS (Auditory Cortex and M1) for Generalized Anxiety Disorder · NA · not yet recruiting
- NCT07112612 — Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer · not yet recruiting
- NCT07112599 — Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis · recruiting
- NCT07176468 — Personalized iTBS in Real-World Clinical Settings for Schizophrenia · NA · recruiting
- NCT07486804 — Effects of taVNS Combined With tACS on Adolescents With Non-Suicidal Self-Injury · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05504330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Medical University
- Last refreshed: 3 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05504330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing